INSANE: Biomarin | Vintage Vibes

A drug can make children with the most common form of dwarfism taller – but height isn’t the same as a better life

A drug that helps children with the most common form of dwarfism grow taller has sparked an ethical debate within the dwarfism community.

The Conversation · Oct 14

A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

Barchart · Dec 22, 2025

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

Benzinga · Oct 28, 2025

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

Barchart · Oct 11, 2024

Innovating in Biotech This Stock Targets Unmet Medical Needs for Big Profit

Most biotechnology companies have a broad mandate to perform research and development that addresses the largest market possible. It makes logical sense, the largest market should be the most profitable. But Biomarin stands this model on its head, providing drug treatments for highly specialized, mostly small markets that are underserved,…

StockNews.com · Jan 4, 2024

Gene therapy for severe hemophilia is approved by FDA

U.S. health regulators have approved a gene therapy for the most common form of hemophilia

The Independent UK · Jun 29, 2023

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga · Aug 24, 2022

BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy

BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Q1 sales reached $519 million, up 7% Y/Y, beating the consensus of $507.52 million. BioMarin said that the increase was achieved "despite continued erosion of the U.S. Kuvan market."  Kuvan is indicated for phenylketonuria. Kuvan still brought in $59.3 million but down from $70.8 million a year ago.…

Benzinga · Apr 28, 2022

BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due…

Benzinga · Feb 24, 2022

FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the 

Benzinga · Feb 18, 2022